Biopsy Guidance System Market Size, Share and Growth Outlook, 2026

Biopsy Guidance System Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Biopsy Guidance System Market size is forecast to increase from $1.45 Billion in 2026 to $2.38 Billion in 2034 at a CAGR of 6.4% between 2026 and 2034.

The Biopsy Guidance System market report provides detailed analysis and outlook of Biopsy Guidance System segments including By Imaging Modality (Ultrasound-Guided Systems, Stereotactic-Guided Systems, MRI-Guided Systems, CT-Guided Systems, X-ray), By Product Category (Manual Guidance Systems, Robotic-Assisted Guidance Systems, Electromagnetic Guidance Systems), By End-User (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers, Physician Practices) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Biopsy Guidance System Industry Overview

Robotic-Assisted Guidance Technologies Advancing Precision Biopsy Procedures

The biopsy guidance system industry is experiencing rapid technological advancement as healthcare providers increasingly adopt robotic-assisted platforms to improve procedural accuracy, reduce invasiveness, and enhance clinical outcomes. A significant development in this area was announced by Quantum Surgical, which acquired medical device company NeuWave Medical, Inc. Through this acquisition, NeuWave’s advanced surgical visualization technologies are being integrated into Quantum Surgical’s Epione robotic-assisted platform. The combined system enables interventional radiologists to perform highly precise planning, targeting, and needle guidance during complex tumor ablations and soft-tissue biopsy procedures. The integration of robotic navigation with advanced visualization capabilities reflects the industry's broader movement toward image-guided intervention systems that improve lesion access while minimizing procedural variability and operator dependency.

Point-of-Care Diagnostic Platforms Expanding Biopsy Guidance Accessibility

The biopsy guidance system industry is also benefiting from the development of portable and non-invasive diagnostic technologies designed to facilitate earlier disease detection and more targeted tissue sampling. Clinical research published in Oxford Academic’s Science and Public Policy highlighted the validation of innovative point-of-care medical technologies within India, including the OralScan platform. Developed by biomedical engineers, OralScan utilizes advanced optical imaging techniques to support automated identification of suspicious oral lesions. In addition to lesion detection, the system provides real-time mechanical guidance for targeted biopsy procedures, helping clinicians improve tissue sampling precision while reducing diagnostic delays. Such innovations demonstrate how portable imaging and guidance systems are expanding access to advanced diagnostic capabilities, particularly in settings where conventional imaging infrastructure may be limited.

Collaborative Oncology Initiatives Driving Imaging and Navigation Innovation

Industry collaboration is accelerating the development of next-generation biopsy guidance systems that combine advanced imaging, software intelligence, and robotic precision. Quantum Surgical strengthened its position in this field by joining the PreciseOnco consortium, a major initiative supported through multi-million-dollar funding from the European Union’s Innovative Health Initiative (IHI). The consortium focuses on integrating sophisticated medical imaging technologies, software-based analytical tools, and robotic guidance systems to improve needle-placement accuracy during interventional oncology procedures. By enhancing targeting precision and procedural safety, these integrated platforms are helping clinicians perform more reliable biopsies while reducing complications associated with tissue sampling. The convergence of robotics, imaging analytics, and precision navigation technologies is positioning biopsy guidance systems as a critical component of modern cancer diagnosis and minimally invasive oncology care.

Biopsy Guidance System Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Biopsy Guidance System market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Hologic, Inc., Becton, Dickinson and Company (BD), Danaher Corporation (Mammotome), FUJIFILM Holdings Corporation, Siemens Healthineers, GE HealthCare, Argon Medical Devices, Inc., Planmed Oy, C. R. Bard (BD Subsidiary), Inrad, Inc.. The Biopsy Guidance System market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Biopsy Guidance System industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Biopsy Guidance System Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Biopsy Guidance System companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Biopsy Guidance System markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Biopsy Guidance System Market Competitive Benchmarking and Company Analysis

Leading companies in Biopsy Guidance System industry include- Hologic, Inc., Becton, Dickinson and Company (BD), Danaher Corporation (Mammotome), FUJIFILM Holdings Corporation, Siemens Healthineers, GE HealthCare, Argon Medical Devices, Inc., Planmed Oy, C. R. Bard (BD Subsidiary), Inrad, Inc.. The Biopsy Guidance System market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Biopsy Guidance System Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Biopsy Guidance System market remains one of the strongest-performing segments in the country.
The US Biopsy Guidance System Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Biopsy Guidance System market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Biopsy Guidance System industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Biopsy Guidance System markets

Canada's strong Biopsy Guidance System sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Biopsy Guidance System market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Biopsy Guidance System Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Biopsy Guidance System market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Biopsy Guidance System population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Biopsy Guidance System industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Biopsy Guidance System market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Biopsy Guidance System sales through 2034

France Biopsy Guidance System companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Biopsy Guidance System Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Biopsy Guidance System distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Biopsy Guidance System Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Biopsy Guidance System market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Biopsy Guidance System industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Biopsy Guidance System industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Biopsy Guidance System Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Biopsy Guidance System market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Biopsy Guidance System market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Biopsy Guidance System Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Biopsy Guidance System Market Segmentation

By Imaging Modality
Ultrasound-Guided Systems
Stereotactic-Guided Systems
MRI-Guided Systems
CT-Guided Systems
X-ray
By Product Category
Manual Guidance Systems
Robotic-Assisted Guidance Systems
Electromagnetic Guidance Systems
By End-User
Hospitals
Diagnostic Imaging Centers
Ambulatory Surgical Centers
Physician Practices

Top Companies in Biopsy Guidance System Industry

Hologic, Inc.
Becton, Dickinson and Company (BD)
Danaher Corporation (Mammotome)
FUJIFILM Holdings Corporation
Siemens Healthineers
GE HealthCare
Argon Medical Devices, Inc.
Planmed Oy
C. R. Bard (BD Subsidiary)
Inrad, Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025